Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.

Molecular pharmacology·1996

Same author

Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant).

Human reproduction (Oxford, England)·1996

Same author

Hydrophobicity and sorption of chlorophenolates to lipid membranes.

Chemosphere·1996

Same author

Inhibition of lipid peroxidation in low-density lipoprotein by the flavonoid myrigalone B and ascorbic acid.

Biochemical pharmacology·1996

Same author

The fourth EF-hand of calmodulin and its helix-loop-helix components: impact on calcium binding and enzyme activation.

Biochemistry·1996

Same author

Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.

Journal of medicinal chemistry·1996

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

TRAIL: a sword for killing tumors.

¹State Key Laboratory of Genetic Engineering, Institute of Genetics, Fudan University School of Life Sciences, Shanghai, PR China. shulinwang@fudan.edu.cn

Current Medicinal Chemistry

|August 18, 2010

Summary

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) shows promise as an anticancer agent. TRAIL-based therapies, including combinations, effectively target cancer cells by inducing apoptosis, with biomarkers guiding personalized treatment strategies.

More Related Videos

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jun 10, 2026

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Area of Science:

Oncology
Molecular Biology
Immunology

Background:

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) selectively induces apoptosis in cancer cells via DR4 and KILLER/DR5 receptors.
Decade-long research elucidates TRAIL signaling in carcinogenesis and therapeutic responses.

Purpose of the Study:

To review the therapeutic potential of TRAIL and its receptor agonists in cancer treatment.
To highlight the role of TRAIL signaling in overcoming apoptosis resistance and enhancing anticancer efficacy.

Main Methods:

Review of preclinical and clinical studies on recombinant TRAIL and agonistic antibodies.
Analysis of combinatorial therapies involving TRAIL-based agents with chemotherapy or radiotherapy.
Examination of biomarkers predicting patient response to TRAIL-based therapies.

Main Results:

Recombinant TRAIL and TRAIL receptor agonists demonstrate potent tumoricidal activity as monotherapies.
Combinatorial therapies amplify anticancer agent activity and broaden the therapeutic window.
Biomarkers are identified for predicting tumor sensitivity to TRAIL-based treatments.

Conclusions:

TRAIL-based therapies offer significant anticancer potential, both as monotherapies and in combination regimens.
Targeting the TRAIL/TRAIL receptor pathway is crucial for overcoming apoptosis resistance in cancer.
Biomarker discovery enables personalized therapeutic strategies for TRAIL-based treatments.